Article
Increased urinary prostaglandin E2 metabolite: A potential therapeutic target of Gitelman syndrome.
PloS one - 1 Jan 2017
Peng Xiaoyan, Jiang Lanping, Chen Chen, Qin Yan, Yuan Tao, Wang Ou, Xing Xiaoping, Li Xuemei, Nie Min, Chen Limeng
Abstract excerpt
BACKGROUND: Gitelman syndrome (GS), an inherited autosomal recessive salt-losing renal tubulopathy caused by mutations in SLC12A3 gene, has been associated with normal prostaglandin E2 (PGE2) levels since 1995 by a study involving 11 clinically diagnosed patients. However, it is difficult to explain why cyclooxygenase-2 (COX2) inhibitors, which pharmacologically reduce PGE2 synthesis, are helpful to patients with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.